JP2017535521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535521A5 JP2017535521A5 JP2017516516A JP2017516516A JP2017535521A5 JP 2017535521 A5 JP2017535521 A5 JP 2017535521A5 JP 2017516516 A JP2017516516 A JP 2017516516A JP 2017516516 A JP2017516516 A JP 2017516516A JP 2017535521 A5 JP2017535521 A5 JP 2017535521A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- modified release
- release formulation
- beta
- lactamase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061507P | 2014-10-08 | 2014-10-08 | |
| US62/061,507 | 2014-10-08 | ||
| US201562126556P | 2015-02-28 | 2015-02-28 | |
| US62/126,556 | 2015-02-28 | ||
| US201562205443P | 2015-08-14 | 2015-08-14 | |
| US62/205,443 | 2015-08-14 | ||
| PCT/US2015/054606 WO2016057744A1 (en) | 2014-10-08 | 2015-10-08 | Beta-lactamase formulations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535521A JP2017535521A (ja) | 2017-11-30 |
| JP2017535521A5 true JP2017535521A5 (enExample) | 2018-11-15 |
| JP6672277B2 JP6672277B2 (ja) | 2020-04-01 |
Family
ID=55653744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516516A Active JP6672277B2 (ja) | 2014-10-08 | 2015-10-08 | ベータラクタマーゼ製剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10105322B2 (enExample) |
| EP (1) | EP3204495B1 (enExample) |
| JP (1) | JP6672277B2 (enExample) |
| KR (1) | KR102467968B1 (enExample) |
| CN (1) | CN107148473B (enExample) |
| AU (1) | AU2015330937B2 (enExample) |
| CA (1) | CA2962959C (enExample) |
| ES (1) | ES2806426T3 (enExample) |
| MX (1) | MX2017004473A (enExample) |
| WO (1) | WO2016057744A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106574273B (zh) | 2014-08-28 | 2021-07-02 | 合成生物制品有限公司 | β-内酰胺酶的基于大肠杆菌的生产 |
| US9744221B2 (en) | 2014-12-23 | 2017-08-29 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| EP3261662B1 (en) | 2015-02-23 | 2021-07-21 | Synthetic Biologics Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
| US10709773B2 (en) | 2015-03-06 | 2020-07-14 | Synthetic Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
| WO2018005606A1 (en) * | 2016-06-28 | 2018-01-04 | Synthetic Biologics, Inc. | Microbiome protection from oral antibiotics |
| CN110062623A (zh) * | 2016-11-01 | 2019-07-26 | 合成生物制品有限公司 | 用于减弱抗生素抗性的方法和组合物 |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| US20200108130A1 (en) * | 2017-03-21 | 2020-04-09 | Synthetic Biologics, Inc. | Beta-lactamase formulations |
| KR20200074982A (ko) * | 2017-10-25 | 2020-06-25 | 다 볼떼라 | 베타-락타마아제 변이체 |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| MX2021001393A (es) * | 2018-08-05 | 2021-04-12 | Da Volterra | Composiciones para el tratamiento de la enfermedad de injerto contra huesped. |
| CA3136833A1 (en) * | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Beta-lactamase compositions for treatment of graft versus host disease |
| WO2021183684A1 (en) * | 2020-03-10 | 2021-09-16 | AI:ON Innovations, Inc. | System and methods for mammalian transfer learning |
| CN112137984B (zh) * | 2020-10-30 | 2023-02-03 | 四川制药制剂有限公司 | 头孢克洛胶囊及其制备工艺 |
| WO2023168316A1 (en) * | 2022-03-04 | 2023-09-07 | Michael Ogburn | Enteric coated dry powdered cannabinoid formulations |
| CN116790567B (zh) * | 2022-12-30 | 2026-03-17 | 扬州大学 | 来源于土壤宏基因组的β-内酰胺酶及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL89987C (enExample) | 1954-05-29 | |||
| US2941995A (en) | 1957-08-02 | 1960-06-21 | Beecham Res Lab | Recovery of solid 6-aminopenicillanic acid |
| US2982696A (en) | 1959-05-01 | 1961-05-02 | Schenley Ind Inc | Ion-exchange procedures for the purification of penicillinase |
| US3070511A (en) | 1960-02-10 | 1962-12-25 | Lepetit Spa | Process for preparing 6-aminopenicillanic acid |
| US3150059A (en) | 1962-12-26 | 1964-09-22 | Lilly Co Eli | Penicillin deacylation via actinoplanaceae fermentation |
| US3239394A (en) | 1964-06-15 | 1966-03-08 | Merck & Co Inc | Process for producing 7-amino-cephalosporanic acid |
| US3499909A (en) | 1966-05-18 | 1970-03-10 | Koninklijke Gist Spiritus | Process for production of 6-aminopenicillanic acid |
| US3488729A (en) | 1966-08-22 | 1970-01-06 | Lilly Co Eli | Cephalothin ester |
| GB1241844A (en) | 1968-08-23 | 1971-08-04 | Beecham Group Ltd | Penicillins |
| GB1463513A (en) | 1974-08-13 | 1977-02-02 | Beecham Group Ltd | Enzymes |
| FI59265C (fi) | 1974-08-13 | 1981-07-10 | Beecham Group Ltd | Foerfarande foer framstaellning av 6-aminopenicillansyra |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| GB2199582A (en) | 1987-01-07 | 1988-07-13 | Bayer Ag | Analogues of pancreatic secretory trypsin inhibitor |
| FR2613624B1 (fr) | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
| CA2007083A1 (en) | 1989-01-09 | 1990-07-09 | Nobuhiko Katunuma | Pharmaceutical use of trypstatin |
| JP2813809B2 (ja) * | 1989-06-19 | 1998-10-22 | 武田薬品工業株式会社 | 有核顆粒製剤およびその製造法 |
| CS275231B2 (en) | 1989-09-29 | 1992-02-19 | Ustav Makormolekularni Chemie | Medicine bottle |
| FI920206A0 (fi) * | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
| DK1078628T3 (da) * | 1994-07-08 | 2009-02-23 | Astrazeneca Ab | Tabletteret flerenhedsdoseringsform |
| JPH08143476A (ja) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | 薬物放出制御膜及び固形製剤 |
| WO1997003185A1 (en) | 1995-07-07 | 1997-01-30 | Novo Nordisk A/S | Production of proteins using bacillus incapable of sporulation |
| PT1121103E (pt) * | 1998-05-18 | 2007-02-28 | Takeda Pharmaceutical | Comprimidos de desintegração oral compreendendo um benzimidazole |
| ES2237121T3 (es) * | 1998-07-28 | 2005-07-16 | Takeda Pharmaceutical Company Limited | Preparacion solida disgregable rapidamente. |
| FI4533U1 (fi) * | 2000-03-14 | 2000-08-10 | Finnzymes Oy | Entsyymikoostumus maidon käsittelemiseksi |
| DK1391502T3 (da) | 2001-05-29 | 2012-05-21 | Kao Corp | Værtsmikroorganismer |
| FI112666B (fi) | 2001-11-06 | 2003-12-31 | Ipsat Therapies Oy | Itiöimätön Bacillus subtilis, sen valmistus ja käyttö |
| FR2843302B1 (fr) | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| EP1564286A1 (en) | 2004-02-11 | 2005-08-17 | Université de Liège | Hybrid proteins of beta-lactamase class A |
| AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
| CN101257892B (zh) | 2005-05-18 | 2013-01-02 | 达沃尔泰拉公司 | 吸附剂的结肠递送 |
| US20070207200A1 (en) * | 2006-03-06 | 2007-09-06 | Pozen Inc. | Dosage forms for administering combinations of drugs |
| FI119190B (fi) | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
| US8273376B2 (en) * | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
| FI119678B (fi) * | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| CN102946872A (zh) * | 2010-05-03 | 2013-02-27 | 阿普塔利斯制药有限公司 | 包含含有胰酶的消化酶混合物的微丸组合物 |
| FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| US9115079B2 (en) * | 2011-07-26 | 2015-08-25 | Meiji Seika Pharma Co., Ltd. | NDM inhibitor |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| CN104080446B (zh) * | 2011-11-30 | 2018-06-29 | 武田药品工业株式会社 | 干包衣片 |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| BR112016023360B1 (pt) * | 2014-04-17 | 2023-03-07 | Synthetic Biologics, Inc | Beta-lactamase e seu uso |
| US9744221B2 (en) * | 2014-12-23 | 2017-08-29 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| US10709773B2 (en) * | 2015-03-06 | 2020-07-14 | Synthetic Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
-
2015
- 2015-10-08 CA CA2962959A patent/CA2962959C/en active Active
- 2015-10-08 KR KR1020177012353A patent/KR102467968B1/ko active Active
- 2015-10-08 CN CN201580059890.6A patent/CN107148473B/zh active Active
- 2015-10-08 ES ES15849110T patent/ES2806426T3/es active Active
- 2015-10-08 AU AU2015330937A patent/AU2015330937B2/en active Active
- 2015-10-08 EP EP15849110.0A patent/EP3204495B1/en active Active
- 2015-10-08 US US14/878,155 patent/US10105322B2/en active Active
- 2015-10-08 JP JP2017516516A patent/JP6672277B2/ja active Active
- 2015-10-08 WO PCT/US2015/054606 patent/WO2016057744A1/en not_active Ceased
- 2015-10-08 MX MX2017004473A patent/MX2017004473A/es unknown
-
2018
- 2018-08-24 US US16/111,477 patent/US10828260B2/en active Active
-
2020
- 2020-09-28 US US17/034,534 patent/US12178917B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| EP3154523A1 (en) | Formulation for oral administration containing mesalazine | |
| JP2008280351A5 (enExample) | ||
| JP2013520467A5 (enExample) | ||
| RU2013106514A (ru) | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи | |
| JP2016535030A5 (enExample) | ||
| HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
| CN107753462A (zh) | 用于保护生物活性剂的基质和层组合物 | |
| EP2034974A2 (en) | Lipoic acid pellets | |
| JP2019513800A5 (enExample) | ||
| SI2773348T1 (en) | PHARMACEUTICAL COMPOSITION OF OMEPRAZOLE | |
| US20140178468A1 (en) | Multiparticulate extended-release composition of mesalamine | |
| WO2017184566A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2017532369A5 (enExample) | ||
| RU2015143891A (ru) | Фармацевтические составы тамсулозина или его солей | |
| KR20200084329A (ko) | 신규한 전달 체계 | |
| JP2023509675A5 (enExample) | ||
| RU2006137660A (ru) | Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423) | |
| JP2019513801A5 (enExample) | ||
| JP2016501226A5 (enExample) | ||
| JP2019534046A5 (enExample) | ||
| US20100172972A1 (en) | Enteric coated pharmaceutical compositions | |
| JP2017008001A5 (enExample) | ||
| WO2018108939A3 (de) | Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron | |
| ES2900975T3 (es) | Preparación farmacéutica oral con revestimiento entérico que comprende fumarato de dimetilo |